The "Clopidogrel Resistance" Trap

American Journal of Cardiology

Volumn 100, Issue 6, 2007, Pages 1044-1046

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HIRULOG; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; SEROTONIN UPTAKE INHIBITOR; SIBRAFIBAN; STATIN; STREPTOKINASE; TICLOPIDINE;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG ELUTING STENT; HEART SURGERY; HUMAN; HYSTERIA; METABOLITE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

EID: 34548420989     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.04.050     Document Type: Note

References (42)

1. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348 (1996) 1329-1339
2. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
3. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
4. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
5. Lev E.I., Patel R.T., Maresh K.J., Guthinkonda S., Granada J., DeLao T., Bray P.F., and Kleiman N.S. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
6. Gachet C., and Aleil B. The inter-individual variability of the response to clopidogrel. Arch Mal Coeur Vaiss 98 (2005) 216-225
7. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
8. Vats H.S., Hocking W.G., and Rezkalla S.H. Suspected clopidogrel resistance in a patient with acute stent thrombosis. Nat Clin Pract Cardiovasc Med 4 (2006) 226-230
9. Duffy B., and Bhatt D.L. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?. Am J Cardiovasc Drugs 5 (2005) 307-318
10. Kapetanakis E.I., Medlam D.A., Petro K.R., Haile E., Hill P.C., Dullum M.K., Bafi A.S., Boyce S.W., and Corso P.J. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?. Circulation 113 (2006) 1667-1674
11. von Heymann C., Redlich U., Moritz M., Sander M., Vargas Hein O., Grubitzsch H., Konertz W.F., and Spies C. Aspirin and clopidogrel taken until 2 days prior to coronary artery bypass graft surgery is associated with increased postoperative drainage loss. Thorac Cardiovasc Surg 53 (2005) 341-345
12. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., and Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
13. Geisler T., Langer H., Wydymus M., Gohring K., Zurn C., Bigalke B., Stellos K., May A.E., and Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27 (2006) 2420-2425
14. Wenaweser P., Dorffler-Melly J., Imboden K., Windecker S., Togni M., Meier B., Haeberli A., and Hess O.M. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
15. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., Lafont A., Camoin L., Walter U., and Eigenthaler M. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59 (2003) 295-302
16. Serebruany V.L. Mortality benefit of no-load clopidogrel in COMMIT: not a surprise. J Cardiovasc Pharm Ther 11 (2006) 99-100
17. von Beckerath N., Taubert D., Pogatsa-Murray G., Wieczorek A., Schomig E., Schomig A., and Kastrati A. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost 93 (2005) 789-791
18. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112 (2005) 2946-2950
19. Kramer J.M., Hammill B., Anstrom K.J., Fetterolf D., Snyder R., Charde J.P., Hoffman B.S., Allen LaPointe N., and Peterson E. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 152 (2006) 454.e1-454.e8
20. Wogen J., and Frech F. Patient adherence with hypertension medication. J Manag Care Pharm 10 (2004) 90-91
21. Burke T.A., Sturkenboom M.C., Lu S.E., Wentworth C.E., Lin Y., and Rhoads G.G. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 24 (2006) 1193-2000
22. Eagle K.A., Kline-Rogers E., Goodman S.G., Gurfinkel E.P., Avezum A., Flather M.D., Granger C.B., Erickson S., White K., and Steg P.G. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 117 (2004) 73-81
23. Cantrell C.R., Eaddy M.T., Shah M.B., Regan T.S., and Sokol M.C. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 44 (2006) 300-303
24. Ho P.M., Spertus J.A., Masoudi F.A., Reid K.J., Peterson E.D., Magid D.J., Krumholz H.M., and Rumsfeld J.S. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 166 (2006) 1842-1847
25. Newby L.K., Bhapkar M.V., White H.D., Moliterno D.J., LaPointe N.M., Kandzari D.E., Verheugt F.W., Kramer J.M., Armstrong P.W., Califf R.M., and SYMPHONY and 2nd SYMPHONY Investigators. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolys 16 (2003) 119-128
26. Komiya T., Kudo M., Urabe T., and Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke 25 (1994) 2337-2342
27. Kuchulakanti P.K., Chu W.W., Torguson R., Ohlmann P., Rha S.W., Clavijo L.C., Kim S.W., Bui A., Gevorkian N., Xue Z., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
28. Hamann G.F., Weimar C., Glahn J., Busse O., Diener H.C., and German Stroke Data Bank. Adherence to secondary stroke prevention strategies-results from the German Stroke Data Bank. Cerebrovasc Dis 15 (2003) 282-288
29. Serebruany V.L., Malinin A.E., and Bhatt D. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events?. Am J Med 119 (2006) 11-16
30. Biondi-Zoccai G.G., Lotrionte M., Agostoni P., Abbate A., Fusaro M., Burzotta F., Testa L., Sheiban I., and Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27 (2006) 2667-2674
31. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55 (2006) 780-784
32. Serebruany V.L., Malinin A.I., Callahan K.P., Binbreck A.S., van de Werf F., Alexander J.H., Granger C.B., and Gurbel P.A. Effect of tenecteplase versus alteplase on platelets in patients during the first three hours of treatment of acute myocardial infarction (the ASSENT-2 Platelet Substudy). Am Heart J 245 (2003) 636-642
33. Verstraete M. Modulating platelet function with selective thrombin inhibitors. Haemostasis 26 suppl (1996) 70-77
34. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias-Guiu J., Rupprecht H.J., and MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
35. CHARISMA Trial Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
36. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
37. Lee C.W., Park K.H., Kim Y.H., Hong M.K., Kim J.J., Park S.W., and Park S.J. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol 98 (2006) 1028-1032
38. Abizaid A., Chan C., Lim Y.T., Kaul U., Sinha N., Patel T., Tan H.C., Lopez-Cuellar J., Gaxiola E., Ramesh S., et al., WISDOM Investigators. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM Registry). Am J Cardiol 98 (2006) 918-922
39. Laarman G.J., Suttorp M.J., Dirksen M.T., van Heerebeek L., Kiemeneij F., Slagboom T., van der Wieken L.R., Tijssen J.G., Rensing B.J., and Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
40. Spaulding C., Henry P., Teiger E., Beatt K., Bramucci E., Carrie D., Slama M.S., Merkely B., Erglis A., Margheri M., et al., TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
41. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
42. Cuisset T., Frere C., Quilici J., Morange P.E., Saidi L.N., Carvajal J., Lambert M., Mouret J.P., Alessi M.C., and Bonnet J.L. Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome. Arch Mal Coeur Vaiss 99 (2006) 889-893